Ximelagatran
Ximelagatran is an oral direct thrombin inhibitor (a prodrug converted to melagatran) that directly blocks the active site of thrombin, inhibiting both free and clot-bound thrombin to prevent fibrin formation and platelet activation. It was investigated as an alternative to warfarin for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. It was withdrawn from the market due to hepatotoxicity (elevated liver enzymes and liver failure) observed with prolonged use.
分子量
473.6000 g/mol
LogP
2.20
TPSA
146.00 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
二维结构
Cite this structure
Embed this structure
SMILES
CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N\O)cc1)C1CCCCC1
InChI
InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
Molecular Formula
C24H35N5O5
HBD / HBA
4 / 7
可旋转键数
11
重原子数
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Ximelagatran is an oral direct thrombin inhibitor (a prodrug converted to melagatran) that directly blocks the active site of thrombin, inhibiting both free and clot-bound thrombin to prevent fibrin formation and platelet activation. It was investigated as an alternative to warfarin for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. It was withdrawn from the market due to hepatotoxicity (elevated liver enzymes and liver failure) observed with prolonged use.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Ximelagatran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL522038. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9574101. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ximelagatran"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ximelagatran/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ximelagatran/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ximelagatran/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ximelagatran"></drugfyi-drug>